Atika Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Atika Capital Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-59,900	Closed	-$3.48M	–	100
2026 Q1	$3.48M	Sell	59,900 -32,606	-35%	-$1.5M	0.44%	51
2025 Q4	$4.15M	Buy	92,506 +54,506	+143%	+$2.29M	0.44%	63
2025 Q3	$1.53M	Buy	+38,000	New	+$1.34M	0.12%	79
2025 Q2	–	Sell	-24,000	Closed	-$805K	–	81
2025 Q1	$805K	Sell	24,000 -48,600	-67%	-$1.85M	0.11%	60
2024 Q4	$2.85M	Sell	72,600 -53,400	-42%	-$2.21M	0.3%	76
2024 Q3	$4.96M	Buy	126,000 +2,000	+2%	+$80.6K	0.51%	59
2024 Q2	$4.83M	Buy	124,000 +2,000	+2%	+$79.9K	0.47%	64
2024 Q1	$5.25M	Buy	122,000 +28,766	+31%	+$1.32M	0.52%	66
2023 Q4	$4.29M	Buy	+93,234	New	+$3.29M	0.58%	60
2023 Q3	–	Sell	-68,050	Closed	-$2.62M	–	104
2023 Q2	$2.62M	Buy	68,050 +600	+0.9%	+$23.9K	0.26%	75
2023 Q1	$2.41M	Buy	+67,450	New	+$2.49M	0.36%	64

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Atika Capital Management's XENE Position: Q2 2026 in Review

Atika Capital Management sold out of Xenon Pharmaceuticals (XENE) in Q2 2026, closing a stake of 59,900 shares — an estimated $3.48M sold.

Atika Capital Management first reported a position in XENE in Q1 2023 and held it in 11 quarters. The position peaked at $5.25M in Q1 2024. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Atika Capital Management reported no remaining Xenon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Atika Capital Management sold 59,900 Xenon Pharmaceuticals shares in Q2 2026, an estimated $3.48M.
Atika Capital Management first reported a position in Xenon Pharmaceuticals in Q1 2023 and held it in 11 quarters.
Atika Capital Management's Xenon Pharmaceuticals position peaked at $5.25M in Q1 2024.
316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Atika Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.